M. et al. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. N. Engl. J. Med. 388, 1478–1490 (2023). Article CAS PubMed Google Scholar Mohs, R. C. & Greig, N. H. Drug discovery and development: role of basic biological research. Alzheimers Dement. 3...
Sotatercept will be further investigated in a Phase 3 clinical program comprised of 4 studies to establish efficacy, safety, and its potential value on top of background therapy across the spectrum of PAH.Methods:\nSotatercept will be administered at a starting dose of 0.3 mg/kg, with a ...
“We couldn’t be more excited that the editors of theNew England Journal of Medicinehave selected the results of the PULSAR trial for publication,” said Habib Dable, President and Chief Executive Officer of Acceleron. “With our STELLAR Phase 3 ...
SUMMIT, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced results from the pivotal, phase 3 MEDALIST trial evaluating the efficacy and safety of investigational luspatercept to treat patients with ring siderobl...
particularly in the setting of advanced age, JAK2 mutation, or significant cardiovascular disease [36,66]. Efficacy of lenalidomide in patients with MDS/MPN-RS-T has also been described [67,68,69,70,71], and the potential use of luspatercept or sotatercept in this population is of signifi...
Methods: This is an ongoing phase-2 study of sotatercept, 0.75 or 1 mg/kg subcutaneously every 3 weeks (1 cycle), in subjects with MF, whether primary (PMF) or post-polycythemia vera/essential thrombocythemia (post-PV/ET MF). Subjects must be RBC-transfusion-dependent (Gale, R.P. ...
Across both cohorts, several responding pts required multiple protocol-specified drug holidays because of Hgb levels ≥11.5 g/dl, with resumption of sotatercept once Hgb was <11 g/dl. Sotatercept was well-tolerated (Table 1, panel B). Grade 3 adverse events possibly related to sotatercept ...
BACKGROUND:This study aims to assess the impact of sotatercept on exercise tolerance, exercise capacity, and right ventricular function in pulmonary arterial hypertension.METHODS:SPECTRA (Sotatercept Phase 2 Exploratory Clinical Trial in PAH) was a phase 2a, single-arm, open-label, multicenter ...
A phase 2, dose-finding study of sotatercept (ace-011) in patients with lower-risk myelodysplastic syndromes (mds) or non-proliferative chronic myelomonocytic leukemia (cmml) and anemia requiring transfusion. Leuk Res. 2015 avril;39, Supplement 1:S5-6....
8 patients had received prior therapies other than RUX, including momelotinib, danazol, pomalidomide, darbepoetin alpha and sotatercept. 10 patients enrolled to the run-in phase. 12 patients had received RBC transfusions prior to study enrollment. A significant increase in platelet count after ...